Skip navigation

State-by-State Requirements and Reporting • Current and Future Policy Initiatives • Operational Best Practices

March 25-26, 2019
  • Philadelphia, PA

Join CBI’s 4th Edition Drug Pricing Transparency Congress to discuss how the future of drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Learn what is driving the new laws of 2019 and proposed objectives of the legislation to grasp best practices and implement strategic steps.

As state and federal legislatures across the nation continue to pass laws aimed at transparency and reporting obligations, drug pricing regulations remain a highlight in the headlines. This leaves numerous unanswered questions and a myriad of legislative and compliance complexities that are going to affect the market in real time. Are you prepared for the impact on drug pricing and compliance practices?

Headline News:

February 26, 2019 Senate Finance Committee hearing —
Drug Pricing in America: A Prescription for Change, Part II
On Tuesday, Pharma gathered at the Senate Finance Committee hearing where the CEOs of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi testified. Highlights include Congress’s desire for Medicare to negotiate drug prices directly, misaligned incentives for PBMs and the financial burden rebates have on the patients and an overall consensus to promote drug transparency.

February 6, 2019 HHS Proposed Rule HHS recently proposed a rule to eliminate (safe harbor) protections for rebates paid to pharmacy benefit managers (PBMs) — the administration, HHS Secretary Azar and even some drug makers support this. PBMs and the PCMA (their trade group) are arguing against this, as it will diminish the role and the business of the middlemen PBM industry.

Headline News quotes
HIGH IMPACT TOPICS
TRANSFORMING PRICING DYNAMICS:
  • Review drug pricing transparency legislation and litigation — Including a deep-dive, state-by-state analysis of laws in Oregon, California and Nevada
  • Explore how the future of drug pricing transparency regulation will impact commercialization, reimbursement and
    drug pricing models
  • Deliver comprehensive legal interpretations of drug pricing transparency and reporting laws currently on the books
    and the policy outlook for 2019
  • Benchmark overall state compliance practices related to
    drug pricing reporting
  • Discuss organizational shifts within legal and compliance departments to handle drug pricing obligations and reporting
SPEAKER PERSPECTIVES:

Biotechnology Innovation Organization (BIO) Boehringer Ingelheim
Cooley LLP Hyman, Phelps & McNamara, P.C. DXC Technology
King & Spalding LLP Mallinckrodt Pharmaceuticals
McDermott Will & Emery LLP Novo Nordisk Pfizer Inc
Pharmaceutical Research and Manufacturers of America (PhRMA)
Porzio Life Sciences, LLC Sanofi Sidley Austin LLP

NEW FOR 2019! Pre-Conference Workshop

4th Edition Drug Pricing Transparency Congress

State-by-State Requirements and Reporting • Current and Future Policy Initiatives • Operational Best Practices

Join CBI’s 4th Edition Drug Pricing Transparency Congress to discuss how the future of drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Learn what is driving the new laws of 2019 and proposed objectives of the legislation to grasp best practices and implement strategic steps.

As state and federal legislatures across the nation continue to pass laws aimed at transparency and reporting obligations, drug pricing regulations remain a highlight in the headlines. This leaves numerous unanswered questions and a myriad of legislative and compliance complexities that are going to affect the market in real time. Are you prepared for the impact on drug pricing and compliance practices?

Headline News:

February 26, 2019 Senate Finance Committee hearing —
Drug Pricing in America: A Prescription for Change, Part II
On Tuesday, Pharma gathered at the Senate Finance Committee hearing where the CEOs of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi testified. Highlights include Congress’s desire for Medicare to negotiate drug prices directly, misaligned incentives for PBMs and the financial burden rebates have on the patients and an overall consensus to promote drug transparency.

February 6, 2019 HHS Proposed Rule HHS recently proposed a rule to eliminate (safe harbor) protections for rebates paid to pharmacy benefit managers (PBMs) — the administration, HHS Secretary Azar and even some drug makers support this. PBMs and the PCMA (their trade group) are arguing against this, as it will diminish the role and the business of the middlemen PBM industry.

Headline News quotes
HIGH IMPACT TOPICS
TRANSFORMING PRICING DYNAMICS:
  • Review drug pricing transparency legislation and litigation — Including a deep-dive, state-by-state analysis of laws in Oregon, California and Nevada
  • Explore how the future of drug pricing transparency regulation will impact commercialization, reimbursement and
    drug pricing models
  • Deliver comprehensive legal interpretations of drug pricing transparency and reporting laws currently on the books
    and the policy outlook for 2019
  • Benchmark overall state compliance practices related to
    drug pricing reporting
  • Discuss organizational shifts within legal and compliance departments to handle drug pricing obligations and reporting
SPEAKER PERSPECTIVES:

Biotechnology Innovation Organization (BIO) Boehringer Ingelheim
Cooley LLP Hyman, Phelps & McNamara, P.C. DXC Technology
King & Spalding LLP Mallinckrodt Pharmaceuticals
McDermott Will & Emery LLP Novo Nordisk Pfizer Inc
Pharmaceutical Research and Manufacturers of America (PhRMA)
Porzio Life Sciences, LLC Sanofi Sidley Austin LLP

NEW FOR 2019! Pre-Conference Workshop